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Abstract
Objective: To assess changes in oral microflora in dental plaque from cancer patients within 7 days of the first 
course of chemotherapy, and the relationship of the changes with mucositis. 
Study Design: Thirty cancer patients, divided into a test group undergoing chemotherapy and a control group no 
undergoing chemotherapy, were enrolled in this pilot study. Oral microflora were cultured from three samples 
of dental plaque at t0 (before chemotherapy), t1 (1 day after chemotherapy) and t2 (7 days after chemotherapy). 
Single and crossed descriptive analyses were used to establish prevalence, and the χ2 test was used to establish the 
statistical significance of the differences observed in distributions (significance level: P<0.05). 
Results: In most patients (57%), oral microflora consisted mainly of Gram-positive cocci, while the remaining 
43% of the bacterial flora also had periodontal-pathogenic species. No Porphyromonas gingivalis appeared in 
the test group. Actinobacillus was the least frequently found bacterium among periodontal pathogens in the test 
group, while Fusobacterium nucleatum was the most frequently found. No significant differences were found in 
quantitative bacterial changes between t0, t1 and t2 in either the test or control groups, or between the two groups. 
According to World Health Organization scores, oral mucositis developed in 10 patients (66.6%) in the test group. 
Conclusions: The results of this pilot study indicate that there were no changes in microflora in dental plaque in 
cancer patients within 7 days of the first course of chemotherapy. No correlations between oral mucositis and 
specific microorganisms were assessed.
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Introduction
The human oral cavity is inhabited by upwards of 500 
species of bacteria (1), most of which are harmless 
commensal organisms. Others, however, are pathogenic 
and are involved in the development of dental caries, 
periodontal diseases, and acute or chronic infections. 
Cytotoxic chemotherapy compromises the oral defense 
mechanisms, either by direct mucosal damage or by 
neutropenia, potentially causing an overall shift in oral 
microflora. In patients undergoing chemotherapy, there is 
an increase in the number and proportion of some bacteria 
associated with periodontal diseases (Actinobacillus 
actinomycetemcomitans, Porphyromonas gingivalis 
and Fusobacterium nucleatum) (2-4), along with a 
diminished effectiveness of immune defense against 
infection (5). Mucositis is an oral complication that 
affects 30–40% of patients receiving chemotherapy and 
radiotherapy and 80% of those undergoing hematopoietic 
stem cell transplantation. It is a multifactorial disease 
defined as epithelial thinning associated with intense 
erythema, ulceration, pain, bleeding and increased risk 
of infection (6). The cytotoxic effects of anticancer drugs 
against high-turnover tissues such as the oral epithelium, 
and the local effects of radiation on the oral mucosa are 
responsible for this event, which compromises quality of 
life and may interfere with management of the disease. 
Mucositis typically appears between 7 and 14 days after 
the initiation of chemotherapy, and is usually preceded by 
a subjective complaint of soreness or a burning sensation. 
Drugs most likely to cause mucositis include doxorubicin, 
bleomycin, fluorouracil, and methotrexate (7). 
It is thought that the incidence and severity of cancer-
chemotherapy-associated mucositis is caused in 
part by changes in the oral bacterial microflora. Oral 
microorganisms are believed to be involved in the 
ulceration phase, where they probably intensify the 
inflammatory process and aggravate or promote the 
formation of ulcers (8). However, until now, it has 
been unclear whether there is an association between 
periodontal pathogens and mucositis (2). 
Given the significant impact of oral mucositis on quality 
of life, it is essential to try to prevent it by all means 
possible. Currently, there are several treatments, but 
none of them has been validated in definitively (9). The 
aim of this pilot study was to assess changes in oral 
microflora in dental plaque in cancer patients within 7 
days from the first course of chemotherapy, and their 
relationship with mucositis. 
Material and Methods
- Patients
We enrolled 30 patients (16 men and 14 women, aged 
32–59 years) with solid malignancy. who had no previous 
adjuvant radiotherapy or recent antimicrobial or antiviral 
treatment. The primary, stage II, squamocellular cancer 
was located in the lungs (5 men and 1 woman), colon–
rectum (8 men and 5 women patients), prostate (3 men) 
and breast (8 women). The study was conducted at the 
Oncology Unit, Fiorini Hospital, Terracina, Italy. The 
study conformed to the Helsinki Declaration and the 
study was approved by the Medical Ethical Committee 
of Sapienza University of Rome. All patients gave 
their written informed consent. The patients were 
divided in two groups of 15: the test group consisted 
of patients undergoing a first course of chemotherapy 
with docetaxel or 5-fluorouracil and oxaliplatin; the 
control group consisted of patients not undergoing 
chemotherapy because of the stage of their disease and 
because they did not have adequate numbers of platelets 
and leukocytes (Table 1). 
- Microbial analysis
Oral mucositis was scored according to World Health 
Organization (WHO) criteria (10) at eight nonkeratinized 
anatomical sites (labial and buccal mucosa, lateral and 
ventral tongue, floor of mouth, and soft palate) by one 
trained dentist (V.C.). Oral microflora were cultured 
from plaque specimens. All patients were sampled at 
time zero (t0) (immediately before chemotherapy), 
and on t1 (1 day after infusion) and t2 (7 days after 
infusion). Control subjects were sampled on equivalent 
dates. Sampling was done at the same time of day, 
approximately 2 h after breakfast. For each individual, 
the supragingival plaque of the right lower premolars 
was collected with a sterile swab. All specimens 
were processed within the following 4 h. Following 
serial dilution, 100 µl of each dilution was plated on 
Schaedler Selective Blood Agar plates supplemented 
with 5% bovine blood (Biolife Italiana, Milan, Italy) 
and incubated in 80% nitrogen/10% hydrogen/10% 
CO2 at 35°C to monitor P. gingivalis, F. nucleatum, 
Actinobacillus spp. and Peptostreptococcus micros. An 
additional 100 μl was plated on Columbia agar containing 
5% bovine blood (Biolife Italiana) in 5% CO2 to monitor 
Gemella spp., Streptococcus spp., Leuconostoc spp., and 
Granulicatella spp. Microorganisms were identified by 
standard procedures (11) as well as the production of a 
set of metabolic enzymes (as tested with Rapid ID 32A 
and Rapid ID32 Strep) (12,13). With regard to bacterial 
counts, the results were expressed in MCF, equivalent 
to 1.5×108 cells/ml. 
- Statistical analysis
Single and crossed descriptive analyses were used 
to establish prevalence, and the χ2 test was used to 
establish the statistical significance of the differences in 
distributions (significance level: P<0.05). The data were 
analyzed using SPSS statistical software.
 
Results
Oral mucositis, according to WHO scores, involving 
nonkeratinized sites developed in 10 patients (66.6%) 
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PATIENT SEX AGE CHEMOTHERAPY DIAGNOSIS 
1 M 49 YES Lung cancer 
2 M 56 YES Colon–rectum cancer 
3 F 32 NO Breast cancer 
4 M 41 NO Colon–rectum cancer 
5 F 44 NO Breast cancer 
6 F 48 NO Lung cancer 
7 F 36 YES Colon–rectum cancer 
8 M 43 YES Prostate cancer 
9 M 59 NO Lung cancer 
10 F 52 YES Breast cancer 
11 M 39 YES Prostate cancer 
12 M 58 YES Colon–rectum cancer 
13 M 45 NO Lung cancer 
14 F 56 YES Breast cancer 
15 F 38 NO Colon–rectum cancer 
16 M 40 NO Colon–rectum cancer 
17 F 57 YES Breast cancer 
18 M 43 YES Colon–rectum cancer 
19 M 39 YES Prostate cancer 
20 M 58 NO Lung cancer 
21 F 46 NO Breast cancer 
22 M 57 YES Colon–rectum cancer 
23 F 55 NO Breast cancer 
24 F 47. NO Colon–rectum cancer 
25 F 41 YES Colon–rectum cancer  
26 M 37 NO Lung cancer 
27 M 58 YES Colon–rectum cancer 
28 F 52 NO Breast cancer 
29 M 48 NO Colon–rectum cancer 
30 F 53 YES Colon–rectum cancer 
Table 1. Patient characteristics.
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in the test group: eight with grade 1 and two with grade 
2. No ulcerations on the keratinized mucosa were 
scored. No mucositis developed in the control group. 
Table 2 shows 17 patients (57%) who developed plaque 
that consisted predominantly of saprophytic Gram-
positive cocci (Streptococcus spp., Leuconostoc spp., 
Granulicatella spp. and Gemella spp.). Nine of these 
patients underwent chemotherapy (53%). The other 13 
PATIENT SEX BACTERIA 
CHEMOTHERAP
Y
N (McF= 1.5 × 108
cells/ml) 
t0 t1 t2 
1 M Granulicatella spp. YES 0.5  0.5 0.45 
2 M Fusobacterium Nucleatum YES 0.3 0.3 0.3 
3 F Gemella spp. NO 0.5 0.5 0.5 
4 M Peptostreptococcus micros NO 0.4 0.4 0.45 
5 F Actinobacillus spp. NO 0.3 0.3 0.3 
6 F Streptococcus spp NO 0.5 0.5 0.5 
7 F Granulicatella spp. YES 0.5 0.5 0.5 
8 M Gemella spp. YES 0.5 0.5 0.55 
9 M Leuconostoc spp. NO 1.5 1.5 1.5 
10 F Fusobacterium Nucleatum YES 0.3 0.3 0.3 
11 M Streptococcus spp YES 0.5 0.5 0.5 
12 M Peptostreptococcus micros YES 0.4 0.4 0.4 
13 M Porphyromonas gingivalis NO 0.3 0.3 0.3 
14 F Actinobacillus spp. YES 0.3 0.3 0.3 
15 F Streptococcus spp NO 0.5 0.5 0.5 
16 M Peptostreptococcus micros NO 0.4 0.4 0.4 
17 F Leuconostoc spp. YES 1.5 1.5 1.5 
18 M Fusobacterium Nucleatum YES 0.3 0.3 0.3 
19 M Streptococcus spp YES 0.5 0.5 0.5 
20 M Streptococcus spp NO 0.5 0.5 0.5 
21 F Porphyromonas gingivalis NO 0.3 0.3 0.3 
22 M Gemella spp. YES 0.5 0.5 0.5 
23 F Fusobacterium Nucleatum NO 0.3 0.3 0.3 
24 F Gemella spp. NO 0.5 0.5 0.5 
25 F Granulicatella spp. YES 0.5 0.5 0.5 
26 M Leuconostoc spp. NO 1.5 1.5 1.5 
27 M Peptostreptococcus micros YES 0.4 0.4 0.4 
28 F Leuconostoc spp. NO 1.5 1.5 1.5 
29 M Porphyromonas gingivalis NO 0.3 0.3 0.3 
30 F Streptococcus spp YES 0.5 0.5 0.5 
Table 2. Mean numbers of bacteria in the study population.
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patients (43%) developed periodontal pathogens (F. 
nucleatum, P. gingivalis, Actinobacillus spp. and Pep. 
micros). Six of these patients (46%) were undergoing 
chemotherapy. No P. gingivalis appeared in the test 
group. Actinobacillus spp. were the least frequently 
found periodontal pathogen in the test group (6.6%), 
while F. nucleatum was the most frequently found 
(20%). No significant differences were found in bacterial 
changes between t0, t1, and t2 in the test group (Fig. 
1). In the control group, the bacterial count remained 
unchanged during the observation period (Fig. 2). At 
t0, t1 and t2, differences in qualitative and quantitative 
variations between the two groups were not significant 
(Fig. 3).
Fig. 1. Mean numbers of bacteria in the samples in the test group.
Fig. 2. Mean numbers of bacteria in the samples in the control group.
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Discussion
Supragingival plaque is influenced by saliva and gingival 
fluid and allows the growth of aerobic and anaerobic 
organisms (14), ultimately leading to complex microflora 
dominated by Gram-positive bacteria, particularly 
streptococci. This flora can be representative of the 
oral flora during chemotherapy (15), as found in our 
present study. The microflora undergo modifications 
during the day, particularly due to eating, and for this 
reason, all sampling was done 2 h after breakfast. The 
standardization of sampling allowed us to minimize 
variations related to this parameter. 
The microorganisms monitored in this study were 
saprophytic species of the oral cavity (Streptococcus 
spp., Leuconostoc spp., Granulicatella spp. and Gemella 
spp.) and species associated with periodontal pathology 
(P. gingivalis, Actinobacillus spp., Peptostreptococcus 
spp. and F. nucleatum). These periodontal pathogens 
are known for their association with periodontal 
diseases in immunosuppressed individuals (15-17). In 
our pilot study F. nucleatum was the most frequently 
found periodontal pathogen in dental plaque of patients 
undergoing chemotherapy. However, none of our patients 
showed any sign of serious periodontal pathology and 
periodontal probing, was not part of the standard of care 
during our study. Therefore, it was not possible to make 
such conclusions from this study. 
The dental plaque flora are constantly influenced 
by external sources, such as nosocomial infections, 
gastroesophageal reflux, and systemic and oral 
treatments. Topical, oral and parenteral antimicrobials 
before and during cancer chemotherapy should alter the 
quantitative and qualitative oral microflora profile (18). 
For this reason, the use of antimicrobial agents was an 
exclusion criterion for our study. Children differ from 
adults in their oral microflora, and in their response to 
chemotherapeutic regimens. Most of the oral bacterial 
changes noted in pediatric studies involved Gram-
positive streptococci and staphylococci, whereas in 
studies of adults, most changes involved Gram-negative 
organisms such as Enterobacteriaceae and Pseudomonas 
spp. (15). 
There is no consensus regarding qualitative and 
quantitative changes in oral microflora during cancer 
chemotherapy, or a clear pattern or association 
between mucositis and changes in oral microflora 
(2). Previous studies have differed in many important 
aspects, including patient populations and presence 
of a control group, chemotherapeutic regimens, use 
of antimicrobials during chemotherapy, sample sites 
and number of samples collected, collection times and 
methods, microorganisms cultured, and the scoring 
method for mucositis. Thus, it is difficult to compare 
our results to those of other studies. Our results showed 
that, although there was a reduction in the number of 
oral bacteria in 5% of patients in the test group, in the 
remaining 95%, there was no significant change in the 
number of bacteria analyzed from t0 to t2. Similarly, 
the test group showed no change in bacterial microflora 
between beginning chemotherapy and at the end of 
treatment. 
The cross-sectional analysis showed no significant 
differences between the test and control groups. In 
slightly more than half of the patients (57%), the oral 
microflora consisted mainly of Gram-positive cocci 
(saprophytic species of the oral cavity), while the 
Fig. 3. Cross-sectional analysis of mean bacterial counts between the two groups.
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remaining 43% of the patients had bacterial flora that 
also had periodontal-pathogenic species. The only 
difference between the two groups was the incidence 
of mucositis, which was present only in the test group. 
These results suggest that bacterial pathogenicity is 
due less to changes in the intrinsic micro-habitat of the 
oral cavity, and more to a decrease in the efficiency of 
the immune response (19). However in this study, the 
relationship between leukocyte counts and quantitative 
oral microflora changes was not determined.
The combination of mucositis and granulocytopenia 
increases the risk of systemic infection resulting from 
invasion of oral microflora into the bloodstream. 
However, although it is postulated that some oral 
bacteria may exacerbate mucositis, it cannot be 
determined from the results that the presence of local 
or systemic bacterial infection correlates with the 
onset and severity of mucositis (20). P. gingivalis was 
consistently associated with oral ulcerations in a study 
of hematopoietic stem cell transplant patients and had 
a positive predictive value (8). P. gingivalis possesses 
several virulence factors such as fimbriae that enable the 
bacterium to at)ach to and invade epithelial cells (21), 
and a lipopolysaccharide capsule that is highly antigenic 
and can induce the production of proinflammatory 
cytokines (22). These virulence factors might prolong 
or intensify oral ulcerations and could explain the role 
of P. gingivalis in mucositis. Nevertheless, in our study, 
no patient undergoing chemotherapy had P. gingivalis 
in the plaque samples. 
Conclusion
Within the limitations of the small sample size of 
our pilot study, it can be concluded that no changes 
occur in microflora in dental plaque in cancer patients 
within 7 days from the first course of chemotherapy. 
No correlations between oral mucositis and specific 
microorganisms were assessed. More patients are 
required to increase the reliability of the results, and 
more detailed studies are necessary to understand 
the relationship between chemotherapy, alterations in 
the nature and magnitude of the oral microflora, and 
the presence of mucositis. Better characterization of 
changes in oral microflora would be obtained using 
molecular biological techniques. This would help our 
understanding of the potential role of oral microflora 
in the development and exacerbation of oral mucositis. 
Data from such work could be directed toward 
developing and testing selective antimicrobial therapies 
for the prevention and management of mucositis during 
cancer chemotherapy. 
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